Monoclonal Antibodies to CGRP or Its Receptor for Migraine Prevention

Abstract

<h2>Abstract</h2> Migraine is a highly prevalent, disabling neurological disease that significantly affects patients' quality of life. There are significant unmet needs in the treatment of migraine, which is often misdiagnosed and undertreated. Monoclonal antibodies targeting the calcitonin gene-related peptide pathway, either the ligand or its receptor, are promising new drugs for the prevention of episodic and chronic migraine. We review the current evidence for these new monoclonal antibodies.